

# Computational Modeling of Developmental Toxicity

Thomas B. Knudsen, PhD Developmental Systems Biologist, US EPA National Center for Computational Toxicology CSS - Virtual Tissue Models Project <u>knudsen.thomas@epa.gov</u> <u>ORCID 0000-0002-5036-596x</u>





Roundtable – "Reproductive Biology and Technology" II International Conference on Reproductive Biology and Toxicology – Botucatu, Brazil Oct 4-6, 2017

**DISCLAIMER:** The views expressed are those of the presenter and do not necessarily reflect Agency policy.

# **Computational Biology**

- On design and fabrication of a minimal cell: "This is the first selfreplicating species we have had on the planet whose parent is a computer." -- Craig Venter, 2010
- On graduate training: "If I were a senior or first-year graduate student interested in biology, I would migrate as fast as I could into the field of computational biology." -- Francis Collins, 2012
- On the problems best-suited to computational biologists: "... finding useful signals in tremendously large sets of unsorted, noisy data." -- Russ Altman, 2012










- Advances in biomedical, engineering, and computational sciences enable highthroughput screening (HTS) to profile the toxicological landscape (*ToxCast/Tox21*).
- Surfeit of HTS data and information now in hand, practical need arises to tie these data in some way to formal biological understanding of toxicity (*MOAs, AOPs*).
- Information must be collected, organized, and assimilated into computer models (*in silico*) that link HTS data (*in vitro*) to apical outcome (*in vivo*) (*predictive toxicology*).
- Computational biology is uniquely position to capture this connectivity and help shift decision-making to mechanistic pathways (*systems models*).

# ... this is not so easy!

- Biological systems are complex: networks of 'nodes' (molecules) and 'edges' (interactions) operate in nonlinear fashion across space and time to control cellular fate and behavior:
  *cell growth, proliferation, adhesion, differentiation, polarization, motility, apoptosis, ...*
- Systems are wired for robustness: cross-talk in cell signaling may dampen how a multicellular system reacts to microphysiological perturbations:
   *how does cellular injury alter developmental dynamics?*
- Agent-Based Models (ABMs): formal approach to explain/predict how changes in a complex dynamical system propagate to a critical effect (eg, malformation).
  - the biological unit (cell) is taken as the computational unit (agent) in a dynamical simulation.

# **Anatomical homeostasis in a self-regulating Virtual Embryo**



SOURCE: Andersen, Newman and Otter (2006) Am. Assoc. Artif. Intel. Building and testing agent-based models models (ABMs) for predictive DART:


- reconstruct tissue development cell-by-cell, interaction-by-interaction
- pathogenesis following synthetic knockdown (cybermorphs)
- introduce ToxCast lesions into a computer simulation
- return quantitative predictions of where, when and how the defect arises.

# **Case Studies for Predictive Toxicology in a 'virtual embryo'**

**CASE 1:** <u>Reverse-engineering the system</u>: *suppose we know an apical outcome (eg, malformation), how far can an ABM take us to inferring a key event quantitatively?* 


**CASE 2:** <u>Forward engineering the system</u>: *suppose we know a molecular effect (eg, ToxCast lesion), how far can an ABM take us to hypothesizing an apical outcome?* 


# **1. Reverse-engineering the system:** *top-down scaling*




SEMs of human palate by K Sulik, UNC

### Hacking the control network $\rightarrow$ 'Cybermorphs'





### Cybermorph -> ToxCast lesion: Captan-induced cleft palate in rabbits



# **Case Studies for Predictive Toxicology in a 'virtual embryo'**


**CASE 1:** <u>Reverse-engineering the system</u>: *suppose we know an apical outcome (eg, cleft palate), how far can an ABM take us to inferring a key event quantitatively?* 

**CASE 2:** <u>Forward engineering the system</u>: *suppose we know a molecular effect (eg, ToxCast lesion), how far can an ABM take us to hypothesizing an apical outcome?* 


# **2. Reverse-engineering the system:** *bottom-up scaling*

### **Blood-Brain Barrier (BBB):**


- Functional interface developing between vascular (and neural compartments of the CNS.
- System evolves in molecular complexity mining the literature landscape identified >90 genes, >5 cell types.
- Archeotypical pathways Glut1, SHH, Notch-DLL ... advanced pathways – neuro/angiogenic signals.



Saili et al. (2017) manuscript under internal review




## **BBB ontogeny:** blueprint of cellular interactions




Saili et al. (2017) manuscript under internal review


# Modeling Brain Angiogenesis: cellular agent-based model of arborization


#### Tata et al. (2015) Mechanism Devel





#### VEGF-A gradient: NPCs in subventricular zone















SOURCE: T Zurlinden – NCCT (2017)

### In silico cascading dose scenario

endothelial tip cellendothelial stalk cellmicroglial cell



Zirlinden et al. (2017) manuscript in preparation

#### INPUT 0.03 μM OUTPUT: predicted dNEL


#### INPUT 0.3 μM: AC50 CSF1R OUTPUT: fewer microglia drawn to EC-tip cells

INPUT 2.0 μM: AC80 CSF1R + AC50 VEGFR3 OUTPUT: overgrowth of EC-stalk cells



INPUT 6.0  $\mu$ M: AC95 CSF1R + AC85 VEGFR3 + AC50 VEGFR2 OUTPUT: loss of directional sprouting 14

# Virtual Embryo: an array of ABMs to forward- and reverse-engineer DevTox.



# **Special Thanks**

Todd Zurlinden – NCCT Kate Saili – NCCT Nancy Baker – Leidos / NCCT Richard Spencer – ARA / EMVL Shane Hutson – Vanderbilt U

# I Center for Computational Toxicology

